Alembic Pharmaceuticals Limited has announced a strong financial performance for the fourth quarter of the fiscal year 2026, with a notable increase in both revenue and net profit. The company reported a 4% year-on-year rise in revenue from operations, reaching ₹1,848 crore. Additionally, the Profit After Tax (PAT) saw a significant 29% increase, amounting to ₹203 crore.
The company’s EBITDA pre R&D also experienced growth, increasing by 8% year-on-year to ₹455 crore, with a pre R&D EBITDA margin standing at 25%. Mr. Pranav Amin, Managing Director of Alembic Pharmaceuticals, attributed the positive results to disciplined execution across the business and a continued focus on profitability and long-term growth investments.
The India Branded Business segment delivered a 4% year-on-year growth, achieving ₹568 crore in revenue for the quarter. Key segments such as gynaecology, gastrology, ophthalmology, and animal healthcare demonstrated encouraging performance. Furthermore, two new products were introduced during the quarter.
Internationally, the US Formulation business grew by 11%, reaching ₹564 crore, with six new launches in the US market. The Ex-US Generics segment recorded revenue of ₹369 crore, and four ANDA approvals were received during the quarter.
Alembic Pharmaceuticals also marked its entry into the US Branded Pharmaceuticals market with the commercial launch of Pivya® through its subsidiary Alembic Therapeutics. Pivya® is positioned as a first-line oral antibiotic option for treating uncomplicated urinary tract infections in women, addressing a market with limited new product introductions.
The API business recorded a 2% growth, reaching ₹347 crore.
Alembic Pharmaceuticals will host an investor call at 5.00 pm IST on May 15, 2026, to discuss the company’s performance further. Interested parties can participate by dialling the provided numbers.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).